Sling Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2020-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://slingtx.com
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Sling Therapeutics, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT06112340
- Locations
- 🇺🇸
Bascom Palmer Eye Institute, Miami, Florida, United States
🇺🇸West Virginia University Eye Institute, Morgantown, West Virginia, United States
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Sling Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05276063
- Locations
- 🇺🇸
Bascom Palmer Eye Institute, Miami, Florida, United States
🇺🇸Sarasota Retina Institute, Sarasota, Florida, United States
🇺🇸Mass Eye and Ear, Boston, Massachusetts, United States
© Copyright 2024. All Rights Reserved by MedPath